



Cutaneous Signs in COVID-19 Patients: A Review

Uwe Wollina¹, Ayşe Serap Karadağ², Christopher Rowland-Payne³, Anca Chiriac^{4,5,6}, Torello Lotti⁷

- 1) Department of Dermatology and Allergology, Städtisches Klinikum Dresden, Academic Teaching Hospital of the Technical University of Dresden, Dresden, Germany.
- 2) Department of Dermatology, Istanbul Medeniyet University, School of Medicine, Istanbul, Turkey.
- 3) Dr Rowland Payne Dermatology, London, UK.
- 4) Apollonia University, Department of Dermatology, Iasi, Romania
- 5) Nicolina Medical Center-Dermatology, Iasi, Romania
- 6) " P.Poni" Institute of Macromolecular Chemistry, Romanian Academy, Iasi, Romania
- 7) Department of Dermatology and Venereology, University of Rome G. Marconi, Rome,

Running title: Cutaneous signs of COVID-19

Conflicts of interests: None.

Funding: None.

Uwe Wollina <https://orcid.org/0000-0001-5933-2913>

Torello Lotti <https://orcid.org/0000-0003-0840-1936>

Correspondence

Uwe Wollina, Department of Dermatology and

Allergology, Städtisches Klinikum Dresden,

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/dth.13549

Academic Teaching Hospital, Friedrichstrasse

41, 01067 Dresden, Germany.

Email: Uwe.Wollina@klinikum-dresden.de

Abstract

COVID-19 pandemic caused by beta-coronavirus SARS-CoV-2 primarily affects the epithelium of the airways. With the increasing involvement of dermatologist in management of this crisis, cutaneous symptoms gained more and more attention. In this review we will describe cutaneous symptoms of patients of all ages in association with COVID-19. We will focus on such disorders that are caused by direct action of the SARS-CoV-2 virus on tissues, complement and coagulation system and on non-specific eruption of the systemic viral infection. Drug-induced reactions are only mentioned in the differential diagnoses. Although more systematic investigations are warranted, it comes clear that some symptoms are clinical signs of a milder COVID-19 course, while others are a red flag for a more severe course. Knowledge of the cutaneous manifestations of COVID-19 may help in early diagnosis, triage of patients and risk stratification.

Key words: COVID-19, SARS-CoV-2, Chilblain-like eruptions, Acro-ischemia, Urticaria, Maculopapular rash, Purpuric rash, Androgenetic alopecia.

Introduction

Since the beta-coronavirus SARS-CoV-2 induced infectious disorder COVID-19 pandemic started in Wuhan city in Central China at the end of 2019, 3.5 million patients have been tested positive world-wide with > 240,000 related death recorded.¹

The virus is mainly spread by droplets, but direct contact and fecal excretions are other possible sources of infection. Vertical transmission may be possible. The primary target of SARS-CoV-2 is the upper respiratory mucosa and angiotensin-converting enzyme 2 (ACE2) acts as a functional receptor for the viral spikes and eventually viral entry into host cells.² Expression of the SARS-CoV-2 cell receptor gene *ACE2* has been demonstrated in a number of human tissues including skin and adipose tissue.³ One of the main reasons of pulmonary consolidation during the active disease is the development of extensive pulmonary fibrosis. SARS-CoV2 induces pulmonary fibrosis in a tumor growth factor-beta (TGF-beta)/Smad-dependent pathway. In both cutaneous and pulmonary fibrosis, trans-differentiation of adipocytes or lipo-fibroblasts into myofibroblasts is involved. Adipocytes can serve as a viral reservoir.⁴

Accepted Article

Incubation time of COVID-19 is up to 14 days. Typical clinical symptoms include fever, dry cough, sore throat, fatigue, diarrhea, conjunctivitis, hyposmia and hypogeusia. Diagnosis is based on medical and travel history, contact to COVID-19 patients, and clinical symptoms.² Confirmation is done by detection of viral RNA by reverse-transcriptase polymerase chain reaction (RT-PCR) for nasopharyngeal swabs or bronchoalveolar fluid. About 50% of nasopharyngeal swabs may be false negative.⁵ Independent factors for severe disease and poor outcome are age > 65 years of life, male gender, cardiovascular disorders and diabetes mellitus.^{6,7} So far, no specific cutaneous pathological findings were reported in autopsied COVID-19 patients.⁸

Skin disease in COVID-19

The initial studies from central China reported low frequencies of skin disease in COVID-19 patients. Among 1099 confirmed cases in Wuhan, only 0.2% presented with cutaneous symptoms.⁹ With a closer involvement of dermatologist in the battle against the latest pandemic, the interest on cutaneous signs of SARS-CoV-2 infection increased.

The first report from Northern Italy on 88 COVID-patients observed cutaneous symptoms in 18 patients (20.4%) of whom 8 patients developed cutaneous signs at the onset, 10 patients after the hospitalization.¹⁰ Unfortunately, neither photographs nor histology was available.

In a recent letter from Thailand, it was stated that almost all COVID-19 patients had cutaneous signs.¹¹ There were no cutaneous signs reported from Tibetan patients living in the high-attitude plateau area, where the course of the disease was generally mild.¹²

We don't know the reason for these different pictures. One explanation might be the involvement of dermatologists in the triage, which will result in a higher rate of skin diseases diagnosed. Another explanation is the setting. Patients with severe disease in ICU will get more attention for all possible

clinical findings compare to those with mild disease and outpatient care. Genetic factors might also contribute, but further studies are needed.

An important initiative to gain valid data has recently been created by the American Academy of Dermatology (AAD) COVID-19 Task Force, who has launched an online COVID-19 dermatology registry: www.aad.org/covidregistry. The primary purpose is to rapidly collect the various cutaneous manifestations.¹³

Acro-ischemia

Severe COVID-19 can lead to a state of hypercoagulation and disseminated intravascular coagulation with laboratory findings such as increased levels of D-dimer, fibrinogen and fibrinogen degradation products, and prolonged prothrombin time. These critical ill patients present acro-ischemia with finger and toe cyanosis, cutaneous bullae and dry gangrene.¹⁴ Livedo-like features and necrosis was noted in 6% of Spanish COVID-19 patients, mostly elderly people. These findings were associated with a mortality rate of 10%.¹⁵ Two more temporary cases were reported in a 47-year-old woman and a 67-year-old male from Atlanta, GA, USA.¹⁶

Histopathological investigations of various tissues in three patients who died from COVID-19 disease revealed hyaline thrombi in microvessels of skin.¹⁷

Chilblain-like eruptions on fingers and toes

Chilblain-like edematous and erythematous eruptions have been observed in milder cases of COVID-19 and in particular in youngsters and young adults, which disappear after the infection without leaving scars.¹⁸ Chilblain like eruptions are mostly asymmetrically distributed. Among 375 COVID-19 patients of Spain, 19% presented with “pseudo-chilblains”. They may be associated with itch or pain

Accepted Article

and disappear on average after two weeks.¹⁵ In a WhatsApp group of French dermatologists 295 cases with cutaneous manifestations were collected. The most common cutaneous finding was chilblain-like eruption with 146 posts.¹⁹ Most of the contributors were dermatologists in private practice with milder cases of possible COVID-19 disease. Chilblain-like lesions in pediatric dermatological outpatients (mean age 14 years) have been noted in 25 children in Spain. None of these children had the typical symptoms of COVID 19, except one who suffered from diarrhea. Two-third of them were males, often the lesions were asymptomatic. Mild pain (22%) or pruritus (11%) were associated symptoms. The lesions disappeared within two weeks without treatment.²⁰ From Lombardy, 14 cases including 11 children (average age 14 years,) and 3 young adults (average age 29 years) with chilblain-like eruptions were reported. There were slightly more females involved. The authors described erythematous-violaceous papules and macules – some with bullae- and digital swelling. Mild itch in was reported in 3 cases.²¹ In a telemedicine attempt from Northern Italy, 63 cases of chilblain-like acral eruption were clinically analyzed. There was no gender preference. Median age was 14 years. Toes and feet were more often affected than fingers or hands. Erythematous-edematous lesions was the predominant feature, while blistering was observed in about half of the cases (**Figure 1**). Pain and itch were reported 27% each, pain with itch occurred in 20.6% of patients. The lesions were completely asymptomatic 25.4%. Median time from the onset to clinical diagnosis was 10 days. COVID-19 disease was mild with pyrexia in less than 5 %.²² In a series of 6 patients with chilblain-like acral eruptions those who were young (15 – 44 years) were either asymptomatic or had only mild symptoms of COVID-19. A 91-year-old male patient was hospitalized but recovered after 3 weeks.²³

In conclusion, chilblain-like eruptions (COVID finger and toes) are signs of milder COVID-19 disease in younger patients. The most important differential diagnoses are perniones and chilblain lupus.



Figure 1: Chilblain-like acral eruptions.

Rash with petechiae /purpuric rash

A skin rash with petechiae resembling Dengue fever has been observed in a COVID-19 patient from Thailand.²⁴ A morbilliform rash sparing palmoplantar skin and mucosa with purpuric features was observed in a 32-year old female occurring 6 days after the onset of COVID-19 symptoms. Five days later, it started healing without leaving scars.²⁵ A 48-year-old symptomatic man from Spain presented with confluent erythematous macules, papules, and petechiae in a symmetric periflexural distribution. Affected were buttocks, popliteal fossae, proximal anterior thighs, and lower abdomen but crural folds, face, palmoplantar skin and mucosa remained uninvolved. A skin biopsy disclosed superficial perivascular lymphocytic infiltrate with abundant red cell extravasation and focal papillary edema. The epidermis showed focal parakeratosis and dyskeratotic cells. There were no signs of thrombotic vasculopathy.²⁶

Other investigators of purpuric skin lesions reported a pauci-inflammatory thrombogenic vasculopathy, with deposition of complement components C5b-9 and C4d in involved and normal-appearing skin, sometimes co-localized with COVID-19 spike glycoproteins.²⁷

In conclusion, rash with petechiae /purpuric rash (**Figure 2**) seems to be a symptom of milder COVID-19 disease. Typically, it spares mucosa and palmoplantar skin. Differential diagnoses include drug-induced rash and rash due to other viral diseases.



Figure 2: Purpuric rash.

Chickenpox-like rash

A chickenpox-like rash with small monomorphic vesicles mainly located on the trunk were noted in middle-aged COVI-19 patients in up to 9% of cases (**Figure 3**).¹⁵ Recalcati (2020) observed one case among 88 severe ill Italian COVID-19 patients.²¹

True chickenpox and acute generalized exanthematic pustulosis are possible differential diagnoses.



Figure 3: Chickenpox-like rash

Urticarial rash

Urticarial rash can be present before the onset of COVID-19 symptoms like cough and pyrexia.²⁸ Two cases have been reported from Belgium – a 39-year-old women and a 71-year-old man who presented with urticarial rash and pyrexia. Both were tested positive for SARS-CoV-2-RNA.²⁹ Spanish groups reported an urticarial rash without mucosal involvement in a 32-year-old female that started 6 days after the onset of COVID-19 disease and another one 10 days after onset of COVID-18 in a 28-year-old woman. Lesions may be morbilliform or larger plaques.^{30, 31} Oral antihistamines improved the symptoms.³⁰

Three severely ill Italian COVID-19 patients presented a wide-spread urticarial rash.²¹ Among 103 French COVID-19 patients only 2 presented with an urticarial rash.³² The frequency of urticarial rash in a larger Spanish study was 19% and was associated to a more severe course of the disease.¹⁵

There is a case report of an acute urticarial rash in a 2-months-old girl from Spain that began on the face and spread all over the body except mucosa and palmoplantar skin. It disappeared after 9 days.³³

In conclusion, urticarial rash in combination with pyrexia is suggestive of COVID-19 disease. Patients present such lesions in the early phase of infection. Acute idiopathic urticaria and urticarial drug-induced rash are major differential diagnoses. Syphilis needs consideration. Many viral infections develop a rash with mucosal involvement in contrast to COVID-19.

Acute rash reminiscent of Symmetrical Drug-Related Intertriginous and Flexural Exanthema (SDRIFE)

A 64-year-old women with diabetes and COVID-19 developed 4 days after the onset of symptoms of the coronavirus infection an erythematous ill-defined rash on both antecubital fossa, that extended

during the following days on the trunk and axillary fold.³⁴ SDRIFE is the most important differential diagnosis.

Erythema multiforme-like rash

Among 27 children with mild disease, two developed targetoid lesions reminiscent of erythema multiforme. They did not suffer from herpes simplex infection.¹⁵ In a study from Northern Italy, 2 children developed targetoid lesions on the hands and elbows a few days after the development of chilblain-like acral eruptions.²¹

In conclusion, erythema multiforme-like lesions are more common in children and associated with a mild COVID-19 course (**Figure 4**). The major differential diagnosis in that age-group is herpes simplex-associated erythema multiforme.



Figure 4: Erythema multiforme-like rash.

Maculopapular rash

Maculopapular rash was noted in 47% of Spanish COVID-19 patients, more than half of them reported pruritus. It lasted for about 9 days and was associated with a more severe course of the coronavirus infection.¹⁵ Histopathological findings have rarely been reported. In on series of 3 elderly patients with erythematous rash from Milan, Italy, microthrombi, lymphocytic vasculitis and Grover-like features

Accepted Article

have been reported.³⁵ Another case of a 57-year-old symptomatic German woman with diffuse fixed erythematous blanching asymptomatic maculopapular lesions, reported mild spongiosis, basal cell vacuolation and mild perivascular lymphocytic infiltrate. Whole skin PCR for SARS-CoV-2 was negative.³⁶ A 67-year-old Italian woman with COVID-19 presented with an ill-defined erythematous pruritic rash, sparing palmoplantar and facial skin, and visible mucosa. Histopathologic examination of a skin biopsy demonstrated a mild superficial perivascular lymphocytic infiltrate in combination with dilated vessels in the upper and mid dermis.³⁷ A morbilliform non-purpuric rash was observed in a 58-year-old Hispanic man without fever that lasted for 6 days. Erythematous lesions were seen on the legs, thighs, forearms, arms, shoulders, and trunk. They aggregated into confluent larger erythematous patches on the trunk. Face, hands, and feet were spared, and intraoral symptoms were reported. He suffered from pain in hands and legs. The exanthema disappeared with topical steroids. RT-PCR was positive for SARS-CoV-2 RNA.³⁸

Maculopapular rash is uncommon among COVID-19-positive children. A 6-year old boy from Barcelona, Spain, developed a maculopapular rash about two weeks after the first COVID-19 symptoms. It is noteworthy, that here the palmoplantar skin became involved. The rash persisted for 5 days.³³

In conclusion, COVID-19-associated maculopapular rash in adult sparse palmoplantar skin and mucosa. It is commonly associated with a more severe course of the disease. Differential diagnoses include measles, Epstein-Barr virus infection, drug-induced exanthema, and graft-versus-host-disease.

Mottling

A 15-day term male neonate with clinical sign of sepsis - fever 38.2°C, tachypnoea, lethargy - presented with mottling of the skin. There were no cough, runny nose or gastrointestinal symptoms. He was tested positive for SARS-CoV-2.³⁹

Pityriasis rosea-like eruptions

Pityriasis rosea-like cutaneous eruption has been reported in an adult patient from Tehran, Iran.⁴⁰ A digitate variant has been observed in an elderly man hospitalized because of severe COVID-19 disease. A skin biopsy revealed mild diffuse epidermal spongiosis, spongiotic vesicles containing lymphocytes and Langerhans cells. The papillary dermis was slightly edematous. In the upper dermis a lymphohistiocytic infiltrate was noted.⁴¹

Unspecified rash

Among 103 COVID-19 patients from France, 2 presented with an unspecified erythematous rash on face and upper trunk.³² Among 88 patients from the Lecco Hospital in Lombardy, Italy, an erythematous rash was noted in 14 patients.¹⁰

Unspecified rash warrants a more detailed diagnosis. Viral exanthema and drug-induced rash are important differential diagnoses.

Androgenetic alopecia

Androgenetic alopecia is driven by androgens and follows a specific pattern of fronto-temporal and vertex regression. Regression affects both hair follicles and sebaceous glands. During the process, local fibrotic structures around and beneath hair follicles develop probably due to adipocyte-myofibroblast transition involving the dermal adipocytes.⁴²

In a clinical study on 41 Caucasian males bilateral pneumonia (COVID-19 disease) and a mean age of 58 years, 29 (71%) had androgenetic alopecia of Hamilton-Norwood scale higher > 2 and 12 (29%), of them 16 (39%) were classified as severe (Hamilton-Norwood scale ≥ 4).⁴³

There are several pathways by which androgens are involved in COVID-19. Androgen-regulated TMPRSS2 protease is a cellular co-receptor required for SARS-CoV-2 infection. The viral spike protein is primed by this enzyme.⁴⁴ Another link is the androgen-driven immune modulation, since androgens are immunosuppressive. Indeed, there is a male predominance among adult COVID-19 patients.^{2, 45} Genetic factors may influence the geographical distribution of COVID-19. The adrenal-permissive phenotype of *HSD3B1* gene encodes 3 β -hydroxysteroid dehydrogenase-1, which is involved in the transformation of dehydroepiandrosterone into active and more powerful androgens. Italy and Spain have the highest frequency of *HSD3B1* allele in the general population, as per the 1000 Genomes Project.⁴⁶ This might explain, why androgenetic alopecia has first been reported from Spain during COVID-19 pandemic.

Conclusions

Cutaneous manifestations of COVID-19 pandemic gain increasing attention since they might be useful in the early diagnosis, triage of COVID-19-positive patients and their risk stratification (**Table 1**).

Chilblain-like acral eruptions, purpuric and erythema multiforme-like lesions have been associated to children and young adult patients who are either asymptomatic or develop a mild disease. In contrast, acro-ischemic lesion and maculopapular rash are often seen among adult patients who run a more severe course. Urticaria with pyrexia has diagnostic significance since this combination is an early symptom of an otherwise not confirmed SARS-CoV-2 infection. Careful registering possible cutaneous manifestations of the COVID-19 pandemic is warranted.

Table 1: Cutaneous sign of COVID-19 disease

Vascular complications	Acro-ischemia Livedo-like Necrosis Chilblain-like eruptions
Maculopapular eruption	Morbiliform Plaques Pityriasis rosea-like eruptions
Urticarial rash	
Vesicular eruption	Vesicle Bullous eruption Chickenpox-like rash
Petechiae/ Purpuric eruptions	
Erythema multiforme-like rash	
Palmar erythema	
<i>Perifollicular eruption</i>	
Pruritus	
Mucosal lesions	Enanthema
Androgenetic alopecia	

References

1. Johns Hopkins Corona Resource Center. <https://coronavirus.jhu.edu> (accessed on May 3rd 2020).
2. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med.* 2020;382(8):727-733.
3. Li MY, Li L, Zhang Y, Wang XS. Expression of the SARS-CoV-2 cell receptor gene *ACE2* in a wide variety of human tissues. *Infect Dis Poverty.* 2020;9(1):45.
4. Kruglikov IL, Scherer PE. The role of adipocyte-like cells in the severity of COVID-19 infections. *Obesity*, in press.
5. Xiao AT, Tong YX, Zhang S. False-negative of RT-PCR and prolonged nucleic acid conversion in COVID-19: Rather than recurrence [published online ahead of print, 2020 Apr 9]. *J Med Virol.* 2020;10.1002/jmv.25855.
6. Wang D, Yin Y, Hu C, et al. Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China. *Crit Care.* 2020;24(1):188.
7. Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. *Clin Res Cardiol.* 2020;109(5):531-538.
8. Yao XH, Li TY, He ZC, et al. [A pathological report of three COVID-19 cases by minimally invasive autopsies]. *Zhonghua Bing Li Xue Za Zhi.* 2020;49(0):E009.
9. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med.* 2020;382(18):1708-1720.

10. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective [published online ahead of print, 2020 Mar 26]. *J Eur Acad Dermatol Venereol*. 2020;10.1111/jdv.16387.
doi:10.1111/jdv.16387.
11. Mungmungpantipantip R, Wiwanitkit V. COVID-19 and cutaneous manifestations [published online ahead of print, 2020 Apr 15]. *J Eur Acad Dermatol Venereol*. 2020;10.1111/jdv.16483.
doi:10.1111/jdv.16483.
12. Lei Y, Huang X, Bamu S, et al. Clinical features of imported cases of coronavirus disease 2019 in Tibetan patients in the Plateau area. *Infect Dis Poverty*. 2020; doi: 10.21203/rs.3.rs-22978/v1.
13. Freeman EE, McMahon DE, Fitzgerald ME, et al. The AAD COVID-19 Registry: Crowdsourcing dermatology in the age of COVID-19 [published online April 16, 2020]. *J Am Acad Dermatol*.
doi:10.1016/j.jaad.2020.04.045.
14. Zhang Y, Cao W, Xiao M, et al. [Clinical and coagulation characteristics of 7 patients with critical COVID-2019 pneumonia and acro-ischemia]. *Zhonghua Xue Ye Xue Za Zhi*.
2020;41(0):E006.
15. Galván Casas C, Català A, Carretero Hernández G, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases [published online ahead of print, 2020 Apr 29]. *Br J Dermatol*.
2020;10.1111/bjd.19163. doi:10.1111/bjd.19163.
16. Manalo IF, Smith MK, Cheeley J, Jacobs R. A dermatologic manifestation of COVID-19: transient livedo reticularis. *J Am Acad Dermatol*. 2020; doi: 10.1016/j.jaad.2020.04.018.

17. Xiaohong Y, Tingyuan L, Zhicheng H, et al. [A pathological report of three COVID-19 cases by minimally invasive autopsies]. *Zhonghua bing li xue za zhi*. 2020; doi: 10.3760/cma.j.cn112151-20200312-00193.
18. Alramthan A, Aldaraji W. A case of COVID-19 presenting in clinical picture resembling chilblains disease. First report from the Middle East [published online ahead of print, 2020 Apr 17]. *Clin Exp Dermatol*. 2020;10.1111/ced.14243. doi:10.1111/ced.14243.
19. Duong TA, Velter C, Rybojad M, et al. Did Whatsapp® reveal a new cutaneous COVID-19 manifestation? [published online ahead of print, 2020 Apr 24]. *J Eur Acad Dermatol Venereol*. 2020;10.1111/jdv.16534. doi:10.1111/jdv.16534.
20. Garcia-Lara G, Laura Linares-González L, Ródenas-Herranz T, Ruiz-Villaverde R. Chilblain-like lesions in pediatrics dermatological outpatients during the COVID-19 outbreak. *Dermatol Ther*. In press.
21. Recalcati S, Barbagallo T, Frasin LA, et al. Acral cutaneous lesions in the time of COVID-19 [published online ahead of print, 2020 Apr 24]. *J Eur Acad Dermatol Venereol*. 2020;10.1111/jdv.16533. doi:10.1111/jdv.16533.
22. Piccolo V, Neri I, Filippeschi C, et al. Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 63 patients [published online ahead of print, 2020 Apr 24]. *J Eur Acad Dermatol Venereol*. 2020;10.1111/jdv.16526. doi:10.1111/jdv.16526.
23. Landa N, Mendieta-Eckert M, Fonda-Pascual P, Aguirre T. Chilblain-like lesions on feet and hands during the COVID-19 Pandemic [published online ahead of print, 2020 Apr 24]. *Int J Dermatol*. 2020;10.1111/ijd.14937.
24. Joob B, Wiwanitkit V. COVID-19 can present with a rash and be mistaken for dengue. *J Am Acad Dermatol*. 2020;82(5):e177.

25. Avellana Moreno R, Villa E, Avellana Moreno V, Estela Villa C, Aparicio M, Fontanella A. Cutaneous manifestation of COVID-19 in images: A case report [published online ahead of print, 2020 Apr 24]. *J Eur Acad Dermatol Venereol*. 2020;10.1111/jdv.16531.
26. Diaz-Guimaraens B, Dominguez-Santas M, Suarez-Valle A, et al. Petechial skin rash associated with severe acute respiratory syndrome coronavirus 2 infection [published online ahead of print, 2020 Apr 30]. *JAMA Dermatol*. 2020;10.1001/jamadermatol.2020.1741.
27. Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases [published online ahead of print, 2020 Apr 15]. *Transl Res*. 2020;S1931-5244(20)30070-0. doi:10.1016/j.trsl.2020.04.007
28. Henry D, Ackerman M, Sancelme E, Finon A, Esteve E. Urticarial eruption in COVID-19 infection [published online ahead of print, 2020 Apr 15]. *J Eur Acad Dermatol Venereol*. 2020;10.1111/jdv.16472. doi:10.1111/jdv.16472.
29. van Damme C, Berlingin E, Saussez S, Accaputo O. Acute urticaria with pyrexia as the first manifestations of a COVID-19 infection [published online ahead of print, 2020 Apr 24]. *J Eur Acad Dermatol Venereol*. 2020;10.1111/jdv.16523. doi:10.1111/jdv.16523.
30. Fernandez-Nieto D, Ortega-Quijano D, Segurado-Miravalles G, Pindado-Ortega C, Prieto-Barrios M, Jimenez-Cauhe J. Comment on: Cutaneous manifestations in COVID-19: a first perspective. Safety concerns of clinical images and skin biopsies [published online ahead of print, 2020 Apr 15]. *J Eur Acad Dermatol Venereol*. 2020;10.1111/jdv.16470. doi:10.1111/jdv.16470.

31. Estébanez A, Pérez-Santiago L, Silva E, Guillen-Climent S, García-Vázquez A, Ramón MD. Cutaneous manifestations in COVID-19: a new contribution [published online ahead of print, 2020 Apr 15]. *J Eur Acad Dermatol Venereol*. 2020;10.1111/jdv.16474. doi:10.1111/jdv.16474.
32. Hedou M, Carsuzaa F, Chary E, Hainaut E, Cazenave-Roblot F, Masson Regnault M. Comment on "Cutaneous manifestations in COVID-19: a first perspective " by Recalcati S [published online ahead of print, 2020 Apr 21]. *J Eur Acad Dermatol Venereol*. 2020;10.1111/jdv.16519. doi:10.1111/jdv.16519.
33. Morey-Olivé M, Espiau M, Mercadal-Hally M, Lera-Carballo E, García-Patos V. Cutaneous manifestations in the current pandemic of coronavirus infection disease (COVID 2019) [published online ahead of print, 2020 Apr 27]. *An Pediatr (Engl Ed)*. 2020;10.1016/j.anpede.2020.04.002.
34. Mahé A, Birckel E, Krieger S, Merklen C, Bottlaender L. A distinctive skin rash associated with Coronavirus Disease 2019? [published online ahead of print, 2020 Apr 15]. *J Eur Acad Dermatol Venereol*. 2020;10.1111/jdv.16471. doi:10.1111/jdv.16471.
35. Gianotti R, Veraldi S, Recalcati S, et al. Cutaneous clinico-pathological findings in three COVID-19-positive patients observed in the metropolitan area of Milan, Italy [published online ahead of print, 2020 Apr 21]. *Acta Derm Venereol*. 2020;10.2340/00015555-3490.
36. Ahouach B, Harant S, Ullmer A, et al. Cutaneous lesions in a patient with COVID-19: are they related? [published online ahead of print, 2020 Apr 30]. *Br J Dermatol*. 2020;10.1111/bjd.19168. doi:10.1111/bjd.19168.
37. Zengarini C, Orioni G, Cascavilla A, et al. Histological pattern in Covid-19 induced viral rash [published online ahead of print, 2020 May 2]. *J Eur Acad Dermatol Venereol*. 2020;10.1111/jdv.16569. doi:10.1111/jdv.16569.

38. Najarian DJ. Morbilliform exanthem associated with COVID-19. *JAAD Case Rep.* 2020; doi: 10.1016/j.jdcr.2020.04.015.
39. Kamali Aghdam M, Jafari N, Eftekhari K. Novel coronavirus in a 15-day-old neonate with clinical signs of sepsis, a case report. *Infect Dis (Lond).* 2020;52(6):427-429.
40. Ehsani AH, Nasimi M, Bigdelo Z. Pityriasis rosea as a cutaneous manifestation of COVID-19 infection [published online ahead of print, 2020 May 2]. *J Eur Acad Dermatol Venereol.* 2020;10.1111/jdv.16579. doi:10.1111/jdv.16579.
41. Sanchez A, Sohier P, Benghanem S, et al. Digitate papulosquamous eruption associated with severe acute respiratory syndrome coronavirus 2 infection [published online April 30, 2020.]. *JAMA Dermatol.* 2020; doi:10.1001/jamadermatol.2020.1704
42. Wollina U, Abdel NM, Kruglikov I. Dermal adipose tissue in hair follicle cycling: possible applications in alopecia? *Georgian Med News.* 2017;(265):41-45.
43. Goren A, Vaño-Galván S, Wambier CG, et al. A preliminary observation: Male pattern hair loss among hospitalized COVID-19 patients in Spain – a potential clue to the role of androgens in COVID-19 severity [published online ahead of print, 2020 Apr 16]. *J Cosmet Dermatol.* 2020;10.1111/jocd.13443.
44. Hoffmann M, Kleine-Weber H, Schroeder S, et al. 2020 SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell,* 2020;181:271.e8–280.e8.
45. Li LQ, Huang T, Wang YQ, et al. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis [published online ahead of print, 2020 Mar 12]. *J Med Virol.* 2020;10.1002/jmv.25757. doi:10.1002/jmv.25757.

46. Sabharwal N, Sharifi N. *HSD3B1* genotypes conferring adrenal-restrictive and adrenal-permissive phenotypes in prostate cancer and beyond. *Endocrinology*. 2019;160:2180–2188.